Authors
Latest:
Breathing New Life into Respiratory Clinical Trials with Digital BiomarkersIncreased data output from the use of devices can accelerate trials for this therapeutic area in need of new therapies.
Latest:
Establishing a Basis for Secondary Use Standards for Clinical TrialsStudy seeks to understand how different forms of data meet the needs of researchers.
Latest:
Addressing the Cost Barrier to Inclusive Clinical TrialsIn an era of rising healthcare expenses, reassurance about costs for patients in diverse communities is particularly important.
Latest:
Digital Biomarkers Solution shows pathway to reduced clinical trial sample sizes, shorter durationsDigital biomarkers provide a pathway to the future where clinical trial sponsors can potentially benefit from reduced trial duration and sample size. Learn more about these benefits from a simulated study.
Latest:
Use of Televisits in Studies and Related PV ConcernsWhile televisits can address many medical concerns, one frequent reservation expressed by healthcare professionals is that patients during these televisits tend to present too narrow a picture of their clinical condition-resulting in non-comprehensive medical assessments.
Latest:
Driving Clinical Speed and Agility Post-COVIDImprovements in data management and collaboration forge path to greater efficiency.
Latest:
Africa is Biosimulation’s Next FrontierThe answers to meeting biosimulation's growing demand for talent may lie in Africa.
Latest:
Unraveling DCT MisconceptionsDCTs can be a great tool for small-to-midsize pharma and biotech companies despite misconceptions of them being advantageous for only Big Pharma.
Latest:
Benchmarking Risks Across Therapeutic AreasStudy uncovers insights on the impact on safety, patient enrollment/retention, and compliance.
Latest:
Lessons Learned in 2022 and the Impact on Drug Development in the Year AheadDCTs and RWD among topics for industry to focus on moving into 2023.
Latest:
Turning Uncertainty into Opportunity: Smarter Clinical Asset Evaluation Powered by Causal Machine LearningMachine learning can help investors dive deeper into trial data to evaluate the true potential of an asset and uncover new hidden opportunities.
Latest:
Language of Medicine: Translating Between German and EnglishThe complexities behind these translations require specialized personnel who are nuanced in both medical cultures.
Latest:
Clinical Trials Are Changing—What Does This Mean For IRT?Expectations for trial design will continue to change, and it’s critical that IRT vendors continue to listen to their customers and evolve their offerings accordingly.
Latest:
FDA Launches Pilot Program Using Cancer Biomarkers to Mitigate RiskFDA’s new voluntary pilot program is designed to help clinicians select appropriate cancer treatments for patients.
Latest:
Rare Disease Patients Overlooked During COVIDSurvey data shows individuals are not informed on how COVID-19 could affect their conditions.
Latest:
Vaccines Approved and Under Development Against COVID-19Today's reality and the hopes of tomorrow of the COVID-19 pandemic—an updated mapping of vaccines authorized by regulatory bodies and those close to it.
Latest:
Referral Partner Integration: Maximize the Efficiency of Patient ReferralsA win-win-win for sites, sponsors, and referral partners.
Latest:
Rare Disease Clinical Trials: Strategies Learned from Duchenne Muscular DystrophyApproaches sponsors, CROs, and investigators can take from the DMD experience.
Latest:
Harnessing Data Analytics and AI for Clinical TrialsBalancing these tools with operational efficiencies can aid CROs in meeting the evolving needs of sponsors.
Latest:
Achieving Successful Decentralized Trials by Leveraging RBQM and Centralized Monitoring OversightAs market factors drive the rapid growth of decentralized clinical trials, organizations should embrace risk-based quality management to evaluate the new dimensions of risk and ensure effective oversight of disparate data sources, writes John Hall.
Latest:
Use of Televisits in Studies and Related PV ConcernsWhile televisits can address many medical concerns, one frequent reservation expressed by healthcare professionals is that patients during these televisits tend to present too narrow a picture of their clinical condition-resulting in non-comprehensive medical assessments.
Latest:
Adapting Site Selection for Clinical Trial Decentralization and the Future LandscapeSites not expected to fade away even as DCTs continue to grow past COVID-19.
Latest:
Standardizing Site Clinical Trial Management with the eISF Reference ModelClinical research sites feel growing pressure to perform work in a compliant manner while keeping pace with stakeholder information exchange workstreams, but lack the consistent processes to do so.
Latest:
Technology-Enabled Real-World Data and Clinical Research Data Integration in a Clinical Registry Ecosystem for FoundationsSpearheaded by disease foundations, the creation of clinical registries is streamlining data collection and driving informed decisions.
Latest:
How Does FSP Models Complement eSource Implementation?Biometric functional services, more than any other, can have a significant impact through the standardization of data collection and management.
Latest:
Sharing Clinical Trial Results with Pediatric ParticipantsSurvey uncovers pediatric-patient perspectives on plain language summaries.
Latest:
Putting Diversity at the Center of Clinical Trials With Real-World DataRobust data sets which can effectively represent diverse populations are key to driving greater inclusivity in trials.
Latest:
Scaling eSource-Enabled Clinical Trials: Hospital PerspectivesThe challenges, opportunities, and strategic outlook for oncology research centers.
